AMD

Oral gildeuretinol demonstrated a clinically meaningful reduction in the geographic atrophy lesion growth rate at 24 months, supporting additional clinical development. SAGA topline data has been accepted as a late breaker at the 128th annual meeting of the American Academy of Ophthalmology, being held October 18-21 in Chicago.

4D Molecular Therapeutics has announced data based on the longest interim follow-up from Phase 1/2 PRISM clinical trial and 4FRONT Phase 3 study design.

Diana Do, MD, spoke with the Ophthalmology Times team about her presentation at the Retina Society meeting focusing on Population Pharmacokinetic Modeling and Simulation of Ocular Clearance for Aflibercept 8 mg and 2 mg.

Meeting in Stockholm provides education, updates, and a taste of culture.

Visual acuity and macular anatomy were maintained, with some changes in fluid management.

Research by investigators at Trinity College in Dublin shows how the gene therapy conferred significant benefit in animal models, and in human cells derived from people with glaucoma.

Data from this trial will be reported ahead of AAO 2024 in Chicago, Illinois.

The next step for the research likely will focus on determining whether blocking GSK3 can reverse existing AMD damage, potentially leading to new treatment options.

According to the company, the pre-clinical safety and efficacy studies of its product have yielded positive results in 3 internationally recognized labs in India, Singapore and the United States.

Pearls for implanting the port delivery device with ranibizumab.

According to the company, the FDA approval strengthens its biosimilar position in the US market.

LUBT010 is a ranibizumab biosimilar to Lucentis and the study achieved its primary endpoint

The company hosted a virtual KOL event focusing on applicability and real-world experience with suprachoroidal drug delivery, the SCS as a differentiator in the retinal treatment landscape with a focus on wet AMD, and ongoing SCS clinical programs.

The company is developing ixoberogene soroparvovec, its clinical-stage gene therapy product candidate, for the treatment of wet AMD.

According to the researchers, the findings suggest drusen formation is a downstream effect of AKT2-related lysosome dysfunction and points to a new target for therapeutic intervention.

The trial will evaluate repeat dosing of axitinib intravitreal implant, (AXPAXLI) for the treatment of patients with wet AMD.

According to the company, OCU410 utilizes an adeno-associated virus platform for the retinal delivery of the RORA gene.

Therapeutics can prevent vision loss and neurodegeneration in patients.

According to the company, its implantable miniature telescope is a Galilean intraocular telescope designed to improve visual acuity and quality of life for patients with late-stage AMD.

A new analysis by researchers at the National Institutes of Health shows the benefit of taking AREDS2 formula in late AMD.

Jennifer Lim, MD, FARVO, FASRS, gives an update on the phase 2 DAVIO 2 trial comparing EYP-1901 with aflibercept at the annual ASRS meeting in Stockholm, Sweden.

6E10 combined with local prophylaxishas been selected for Phase 3 pivotal trials, with a favorable safety profile and potential best-in-class product profile at 26 weeks.

4D-150 Is being evaluated in wet age-related macular degeneration (AMD).

The key factor may be the control of inflammation.

Researchers from the UKB Eye Clinic, in cooperation with the University of Bonn and in close collaboration with basic and clinical scientists, have examined patients with early forms of AMD. The researchers focused on the so-called iRORA lesions, which are very early anatomical signs of retinal damage.

A novel formulation may prevent blood vessel growth and vascular leakage in the retina.

A team of researchers at the Ohio State University found that in mice an enzyme related to cell growth and division is a culprit in the blood vessel invasion in the back of the eye that causes blurred central vision in wet AMD.

Chris Brittain, vice president, Global Head of Ophthalmology Product Development at Genentech, sat with Ophthalmology Times to discuss the company's plans with Susvimo following the FDA approval for relaunch.

The company announced it has received FDA approval to relaunch Susvimo for intravitreal use via an ocular implant for treating people with wet AMD.